Skip to main content
MyDeficiencies

Thyrotropin alfa

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Thyrotropin alfa is a recombinant glycoprotein, structurally and functionally intended to match endogenous pituitary TSH, given by intramuscular injection as a two-dose regimen (0.9 mg, then 0.9 mg 24 hours later) rather than as a chronic oral medication. Its own FDA label describes no hepatic CYP450 metabolism and no enzyme induction or inhibition of any kind; the drug is not absorbed through the gut at all (it is injected), so none of the classical absorption-interference mechanisms (chelation, gastric pH change, transporter competition, bile-acid sequestration) that drive most drug-nutrient depletion findings are mechanistically available to it. Its mean apparent elimination half-life is 25±10 hours, and the label states plainly that "the organs responsible for the clearance of THYROGEN have not been definitively identified," though clearance is presumed renal and/or hepatic by analogy to pituitary-derived TSH. Renal impairment slows this further: elimination is "significantly slower" in dialysis-dependent end-stage renal disease, producing a prolonged TSH elevation. None of this constitutes classical depletion machinery, and the Step 2 mechanism screen found no present mechanism (absorption interference, hepatic-enzyme-induced catabolism, renal electrolyte wasting, cofactor antagonism, or microbiome disruption) for any classical nutrient. That null result is itself the headline: a drug given once or twice, cleared like a protein rather than metabolized like a xenobiotic, has essentially no exposure window in which a chronic nutrient-depletion effect could plausibly accumulate.

ATC H01AB01 (thyrotropin) · also sold as Thyrogen (Genzyme and a Sanofi company) · reviewed 2026-09-28. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Thyrotropin alfa in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, extrathyroidal TSH-receptor stimulation of brown-adipocyte mitochondrial uncoupling

Yellow — Low

See study details

TSH receptors are expressed outside the thyroid, including on brown and white adipocytes. TSH stimulation of these extrathyroidal receptors has been described as increasing brown-adipocyte uncoupling protein-1 (UCP-1) expression, a genuine mitochondrial inner-membrane mechanism, but the supporting evidence is rodent-model-heavy and was not derived from thyrotropin-alfa-treated patients.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW

Limits on what this shows

  • Key null/negative: None identified specific to thyrotropin alfa; no human study of brown-adipose UCP-1 or mitochondrial markers after thyrotropin alfa administration was located.
  • At-risk subgroups: Cannot be determined. Adult humans carry comparatively little metabolically active brown adipose tissue relative to the mouse models underlying this literature, a translational gap disclosed here rather than smoothed over, and the drug's own diagnostic exposure is a single two-dose course rather than sustained dosing.

Regulatory status

Not addressed in the Thyrogen label.

Population evidence

Williams GR. "Extrathyroidal expression of TSH receptor." Ann Endocrinol (Paris) 2011;72(2):68-73 (DOI 10.1016/j.ando.2011.03.006). Narrative review, Tier C. States the TSH receptor is expressed "widely in a variety of extrathyroidal tissues including... white and brown adipose tissue; orbital preadipocyte fibroblasts and bone," and that in brown adipocytes, TSH stimulation produced "increased cAMP activity, reduced Tshr mRNA expression and increased expression of the type 2 iodothyronine deiodinase and uncoupling protein-1 (UCP-1)," citing supporting data from TSH-receptor-knockout mice. Only this review itself was opened this session; the primary rodent studies it cites were not independently opened and are not separately tier-counted.

Mechanism

UCP-1 sits in the inner mitochondrial membrane and dissipates the proton gradient as heat rather than channeling it through ATP synthase. Upregulating it via TSH-receptor cAMP signaling in adipocytes is a genuine mitochondrial-membrane-function change, mechanistically distinct from and additional to the drug's intended thyroid-follicular-cell target.

Overlap

Shares its underlying source (Williams 2011) with the ATP production entry below; see Overlap map. Do not read the two entries as independent confirmation of a single effect.

Counter-evidence held on record

Rodent-model and knockout-mouse receptor-biology evidence, not measured in thyrotropin-alfa-treated humans, and not comparable in duration to the drug's single two-dose diagnostic regimen. No supplement or intervention follows from this entry.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, TSH-receptor-driven thyrocyte H2O2 generation via the iodide-organification pathway

Yellow — Low

See study details

TSH-receptor activation of the thyrocyte cAMP cascade is described in the literature as inducing the same NADPH-oxidase (DUOX)-dependent hydrogen peroxide system thyroid cells use to organify iodide onto thyroglobulin. Because thyrotropin alfa's entire diagnostic mechanism is delivering a TSH-receptor stimulus to residual thyroid tissue, this is a real, drug-mechanism-adjacent redox signal, but the supporting data are porcine and canine thyrocyte studies described in a narrative review, not measurements in thyrotropin-alfa-treated humans.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW

Limits on what this shows

  • Key null/negative: None identified specific to thyrotropin alfa; no human study measuring a redox or oxidative-stress biomarker before and after thyrotropin alfa administration was located despite multi-phrasing Crossref search ("thyrotropin alfa oxidative stress", "TSH thyroid peroxidase DUOX hydrogen peroxide oxidative stress").
  • At-risk subgroups: Cannot be determined for thyrotropin alfa specifically. If this mechanism is active at all in a diagnostic patient, exposure would be bounded to residual thyroid remnant tissue over roughly the 24-72 hour window of peak TSH stimulation (mean apparent elimination half-life 25±10 hours per label), not systemic or chronic.

Regulatory status

Not addressed in the Thyrogen label; the label does not discuss oxidative stress, redox markers, or reactive oxygen species at all.

Population evidence

Carvalho DP, Dupuy C. "Role of the NADPH Oxidases DUOX and NOX4 in Thyroid Oxidative Stress." Eur Thyroid J 2013;2(3):160-167 (DOI 10.1159/000354745). Narrative review, Tier C, no primary cohort of its own. States that "high concentrations of H2O2 were detected at the apical surface of thyrocytes, where thyroid hormone biosynthesis takes place," traces this to DUOX1/DUOX2, and describes (without this dossier independently opening) two animal studies it cites: "the Ca2+- and reduced nicotinamide adenine dinucleotide phosphate-dependent hydrogen peroxide generating system is induced by thyrotropin in porcine thyroid cells," and "tonic modulation of dog thyrocyte H2O2 generation and I- uptake by thyrotropin through the cyclic adenosine 3',5'-monophosphate cascade." Per this protocol's citation rule, only the Carvalho/Dupuy review itself counts as an opened, read source; the porcine and canine primary studies it describes are disclosed here but not independently verified this session and are not separately tier-counted.

Mechanism

TSH-receptor activation of the cAMP cascade is described as inducing thyrocyte DUOX-mediated H2O2 production, the same H2O2 that thyroid peroxidase then uses as a cosubstrate to organify iodide onto thyroglobulin. This is the normal physiological mechanism of thyroid hormone synthesis, not a described off-target toxicity, and the same review notes that DUOX2 loss-of-function mutations cause hereditary hypothyroidism rather than protecting against oxidative injury.

Counter-evidence held on record

This describes the normal, intended biochemistry by which the drug's TSH-receptor stimulus enables thyroglobulin release and radioiodine uptake, not a toxic or deficiency-causing effect, and the underlying animal data were not independently opened this session. Not a rationale for any antioxidant supplement, and not evidence that thyrotropin alfa causes measurable systemic oxidative stress in a diagnostic patient.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No evidence at any tier connects thyrotropin alfa, or TSH/TSH-receptor signaling generally, to copper or ceruloplasmin status, and no circulating consumer claim exists to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: Both UNGRADED conditions are met: (1) no Tier B/C evidence links thyrotropin alfa or TSH-receptor signaling to copper or ceruloplasmin; a dedicated Crossref query returned a large general TSH-receptor bibliography (structure, genetics, autoimmune disease) with zero on-topic hits; (2) no circulating consumer claim naming thyrotropin alfa or Thyrogen and copper was found. US Pharmacist's and chiro.org's drug-nutrient-depletion compilations were both opened and searched directly; neither mentions Thyrogen, thyrotropin alfa, or any thyroid diagnostic agent at all. Thyrogen-specific consumer pages (Drugs.com side-effect listing, ThyCa.org) were also opened and contain no mineral or "detox" content.

Search channels tried

PubMed search-listing pages (HTTP 429, proxy rejection with explicit do-not-retry instruction, at session start); Europe PMC REST API, its website, and the europepmc.org frontend (429/robots-disallowed on all three attempts); NCBI eutils esearch and PMC/Bookshelf (robots-disallowed); Semantic Scholar API and web frontend (429/robots-disallowed); OpenAlex API (429, twice, with backoff); Google, Bing, and DuckDuckGo HTML search (all robots-disallowed); BASE search (access denied, bot-protection page); Lens.org (403); WebSearch tool (session budget already exhausted, 200/200, before this task's first query). The Crossref API became reachable after adding a contact (mailto) parameter and pacing requests 60-90 seconds apart, and returned real, readable results for two dedicated copper/ceruloplasmin queries plus the general TSH-receptor bibliography search; it is the channel credited with this genuine null result. This reflects both a real evidence gap (thyrotropin alfa's only approved use is a one-to-two-dose diagnostic/adjunct course, giving little clinical occasion to study trace-mineral depletion in this population) and a partially degraded-tooling session, disclosed as two distinct things rather than blended together. A brief re-check during this revision (a combined Crossref query covering copper, ceruloplasmin, gut microbiome, hemoglobin, and oxygen together) again returned only unrelated hydroxyurea-microbiome, ceruloplasmin-carcinoma, and general gut-physiology titles, no on-topic result; this entry's grade is unchanged.

Iron

Not graded — disclosed evidence gap

See study details

No evidence at any tier connects thyrotropin alfa, or TSH/TSH-receptor stimulation generally, to a change in iron, ferritin, or heme status, and no circulating consumer claim exists to rebut. Thyroid peroxidase is a genuine, well-characterized heme (iron-containing) enzyme, but a second, dedicated re-attempt this revision still found no source linking that structural cofactor requirement to any TSH-driven or thyrotropin-alfa-driven change in iron demand, uptake, or status.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: Both UNGRADED conditions remain met after a full re-attempt: (1) this revision located and opened two classic, drug-independent biochemistry papers establishing that thyroid peroxidase carries a heme prosthetic group, Taurog, Lothrop and Estabrook 1970 and Alexander and Corcoran 1962 (both cited below), confirming the mechanistic premise is real, established enzymology; but neither paper discusses TSH or thyrotropin regulation of that cofactor requirement, and a further round of dedicated searches (PubMed search-listing pages for "TSH regulation thyroid peroxidase gene expression heme"; Crossref for "recombinant TSH thyroid stimulation iron uptake thyroglobulin iodination"; Europe PMC and Semantic Scholar for "thyroid peroxidase iron TSH regulation") found no source, at any tier, stating that TSH-receptor stimulation increases thyroidal iron uptake, heme synthesis, or TPO-bound iron turnover as a regulated, measurable event, the way the Oxidative stress entry's DUOX induction is described. A heme prosthetic group is also not consumed catalytically the way a cofactor like NADPH is, so the biochemical case for a stimulable "iron demand" from TPO activity is intrinsically weaker than the DUOX/H2O2 case already graded yellow above, and this distinction is disclosed rather than glossed over. (2) No circulating consumer claim naming thyrotropin alfa/Thyrogen and iron, ferritin, or anemia was found in the same sources checked for Copper, re-confirmed this revision. The DailyMed label itself was also re-read in full this revision specifically for hemoglobin, hematocrit, iron, ferritin, complete-blood-count, or anemia language in the clinical-trials, adverse-reactions, and clinical-studies sections; none appears anywhere in the label.

Search channels tried, this revision

PubMed search-listing pages: reachable this session (unlike the original review) for one query ("thyrotropin alfa iron"), returning two off-topic results (a roxadustat/hemodialysis iron-and-thyroid paper not involving thyrotropin alfa, and an interferon-induced thyroiditis case report), but a second, more specific query ("TSH regulation thyroid peroxidase gene expression heme") was blocked by a reCAPTCHA interstitial rather than returning results, so PubMed access this session was inconsistent rather than fully restored. Europe PMC REST API: HTTP 429 with an explicit do-not-retry instruction on two separate queries. Semantic Scholar API: HTTP 429 on two separate queries. OpenAlex API: HTTP 429. Crossref API (mailto parameter, paced requests): reachable and productive for three queries, surfacing the two heme-characterization papers above and returning zero on-topic hits for hematologic and iron-uptake-specific phrasings, before itself returning an HTTP 429 do-not-retry response on a fourth query. WebSearch tool: session budget still exhausted (200 of 200 calls) for both a general and a mechanism-specific query. NCBI Bookshelf: attempted via a StatPearls-style URL guess, which resolved to an unrelated chapter (postpartum pubic symphysis diastasis), confirming that without a working search interface this channel cannot be reliably targeted from a URL guess alone. This is a broader, multi-phrasing re-attempt than the original review's single blocked pass, and it upgrades confidence that the heme-cofactor mechanism itself is real and citable, while confirming that no source ties it to thyrotropin alfa or to TSH-driven iron demand specifically. A future revision should retry once PubMed's search-listing pages stop presenting a reCAPTCHA interstitial and Europe PMC/Semantic Scholar/OpenAlex rate limits clear, ideally with author-level searches for any TSH-receptor knockout or Graves-disease iron-status literature not surfaced by these keyword queries.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No evidence at any tier connects thyrotropin alfa to gut microbiome composition or diversity, and no circulating consumer claim exists to rebut; the drug's intramuscular route also lowers prior mechanistic plausibility relative to an orally dosed drug.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: Both UNGRADED conditions are met: (1) a dedicated Crossref query combining thyrotropin/TSH with gut microbiota/microbiome terms returned general TSH-receptor and unrelated gut-physiology book-chapter results, none connecting the two; because thyrotropin alfa is injected intramuscularly and never contacts the gastrointestinal tract, the Step 2 mechanism-screen categories most associated with microbiome disruption (direct GI mucosal exposure, oral antibiotic-like activity, altered gut transit) are not mechanistically present for this drug, which is disclosed here as reasoning rather than treated as a substitute for the literature search itself; (2) no circulating consumer claim naming thyrotropin alfa/Thyrogen and gut health, microbiome, or digestion (beyond the labeled, already-disclosed transient nausea and vomiting, which are adverse-reaction symptoms, not microbiome claims) was found in the sources checked.

Search channels tried

Same blocked-channel set documented under Copper. Crossref API (reachable channel) was queried with "recombinant TSH thyrotropin gut microbiota microbiome" and returned no on-topic result among returned works. Disclosed as a genuine evidence gap for a short-course injectable biologic, compounded by the same partial tooling degradation affecting every category in this review. Re-checked briefly this revision alongside Copper and Oxygen delivery/utilization (see Copper's entry for the combined query and result); grade unchanged.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production, the same TSH-receptor-driven mitochondrial uncoupling would be expected to reduce, not raise, ATP yield in the affected tissue

Yellow — Low

See study details

The UCP-1 upregulation described under Mitochondrial burden mechanistically uncouples oxidative phosphorylation from ATP synthesis. To the extent this extrathyroidal TSH-receptor pathway is active, it would be expected to reduce ATP-coupling efficiency in that specific tissue, the reverse of a nonspecific "boosts energy" framing sometimes attached to thyroid-axis drugs generally.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW

Limits on what this shows

  • Key null/negative: None identified specific to thyrotropin alfa; not measured in any thyrotropin-alfa-treated human population located this session.

Population evidence

Same source as Mitochondrial burden: Williams GR, Ann Endocrinol (Paris) 2011;72(2):68-73. No additional independent source for ATP production specifically was located despite a dedicated Crossref query ("thyrotropin alfa mitochondrial ATP cellular energy").

Mechanism

UCP-1-mediated proton leak converts the mitochondrial proton-motive force to heat instead of ATP-synthase-driven ATP production. This is established uncoupling-protein biochemistry applied to a TSH-receptor-activated tissue context, not a new or drug-specific pathway.

Overlap

Shares its source with Mitochondrial burden above; see Overlap map. This is one dataset viewed through two required category lenses, not two independent lines of evidence.

Counter-evidence held on record

A reverse-direction, tissue-specific mechanistic note (less ATP-coupling efficiency in brown fat, not systemic "low energy"), drawn from rodent-model receptor biology and not from any measurement in a patient given thyrotropin alfa. Must not be read as evidence that thyrotropin alfa depletes cellular energy, and no supplement or dosing guidance follows from it.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No evidence at any tier connects thyrotropin alfa to hemoglobin, hematocrit, red-cell mass, or tissue oxygen delivery as a direct drug effect, and no circulating consumer claim exists to rebut. General hyperthyroid physiology (increased cardiac output and oxygen consumption) is excluded here as the drug's own intended/associated pharmacologic cascade, not a nutrient-style hematologic finding.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: Both UNGRADED conditions are met: (1) no Tier B/C evidence links thyrotropin alfa directly to hemoglobin, hematocrit, or red-cell mass; a dedicated Crossref search on thyrotropin alfa and hemoglobin/erythropoiesis/oxygen returned only a general, non-drug-specific sickle-cell erythropoiesis paper and the drug's own definitional entry, neither relevant. General endocrinology literature ties thyroid hormone status broadly to erythropoiesis and cardiac oxygen consumption, and the label's own hyperthyroidism and stroke warnings describe a hyperthyroid, higher-metabolic-demand state, but per Hard Rule 2 those trace back to the drug's intended pharmacologic target (stimulating thyroid hormone synthesis/release) and its labeled clinical adverse effects, not to a directly measured hemoglobin/hematocrit/red-cell-mass change, so they are excluded here rather than filed as an oxygen-delivery finding; (2) no circulating consumer claim naming thyrotropin alfa/Thyrogen and anemia, hemoglobin, or "oxygen delivery" was found in the sources checked.

Search channels tried

Same blocked-channel set documented under Copper. Crossref API was queried twice with hemoglobin/erythropoiesis/oxygen phrasing and separately with cardiac-output/oxygen-consumption/tachycardia phrasing tied to thyrotropin alfa specifically; neither returned a drug-specific hematologic study. Disclosed as a genuine evidence gap for a short-course diagnostic agent, compounded by the same partial tooling degradation affecting every category in this review. This revision also re-read the DailyMed label in full specifically for hemoglobin, hematocrit, or complete-blood-count language (see the Iron entry above) and confirmed none appears; re-checked briefly alongside Copper and Gut microbiome risk this revision, grade unchanged.

All references used above
  1. THYROGEN (thyrotropin alfa) for injection, full prescribing information. — DailyMed, National Library of Medicine, manufacturer Genzyme Corporation (a Sanofi company), setid b52dfa36-f90b-4e19-9b5e-26db9d04df2b, labeling last updated February 24, 2023. Opened in full; source for the pharmacokinetic basis, mechanism, dosing regimen, hyperthyroidism/stroke/tumor-expansion warnings, adverse-reaction rates, renal-impairment elimination note, and pregnancy/lactation contraindications.
  2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code H01AB01. — atcddd.fhi.no (redirected from whocc.no). Opened directly; confirms ATC code H01AB01 corresponds to thyrotropin (thyrotropin alfa) and lists a defined daily dose of 5 U (biological) for the class entry. Primary regulatory-adjacent source, not a tertiary listing.
  3. Thyroid-stimulating hormone. — Wikipedia. Opened; used only for general TSH background (structure, feedback loop, half-life of endogenous pituitary TSH, historical discovery), not as evidence for any graded entry. General reference only.
  4. Williams GR. Extrathyroidal expression of TSH receptor. — Ann Endocrinol (Paris) 2011;72(2):68-73 (DOI 10.1016/j.ando.2011.03.006). Narrative review, Tier C. Opened via ScienceDirect (abstract-level detail). Source for the Mitochondrial burden and ATP production entries (brown-adipocyte UCP-1 upregulation) and the Overlap map row linking them.
  5. Carvalho DP, Dupuy C. Role of the NADPH Oxidases DUOX and NOX4 in Thyroid Oxidative Stress. — Eur Thyroid J 2013;2(3):160-167 (DOI 10.1159/000354745). Narrative review, Tier C. Opened via karger.com (abstract-level detail). Source for the Oxidative stress entry; the porcine/canine primary studies it describes were not independently opened this session and are disclosed as such within that entry.
  6. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. — J Clin Endocrinol Metab 2003;88(9):4110-4115 (DOI 10.1210/jc.2003-030298). Human comparative study (rhTSH-with-withdrawal, n=16, vs. L-T4-withdrawal-only, n=24), Tier A for this drug. Opened via academic.oup.com (abstract-level detail). Source for the Monitoring panel's iodine-intake/procedural note; disclosed that its urinary-iodine finding concerns L-thyroxine's own iodine content, not thyrotropin alfa's pharmacology directly, and is not used to grade a classical Iodine entry for that reason.
  7. Seekins et al. Thyrotropin-alfa: Nausea: case report. — Reactions Weekly 2025 (DOI 10.1007/s40278-025-83271-2). Drug-specific case report. Located via Crossref API metadata (title, journal, year, DOI); the full text on link.springer.com was blocked by the WebFetch proxy (HTTP 429, explicit do-not-retry response) on every attempt. Not opened or read this session; not used as evidence for any grade, listed for disclosure only.Full text blocked by the WebFetch proxy (HTTP 429, explicit do-not-retry response); not opened this session.
  8. Thyrotropin-alfa: Multinodular goiter leading to precipitation of thyroid storm: case report. — Reactions Weekly 2025 (DOI 10.1007/s40278-025-73936-9). Drug-specific case report. Located via Crossref API metadata only; its title independently corroborates the label's own hyperthyroidism/thyroid-storm warning, but the full text on link.springer.com was blocked by the WebFetch proxy (HTTP 429, explicit do-not-retry response). Not opened or read this session; title-only mention used solely as disclosed corroborating context in the headline finding, not as independent tier-raising evidence, and not used for any graded nutrient/category entry (thyroid storm is a clinical outcome excluded under Hard Rule 2, not a nutrient finding).Full text blocked by the WebFetch proxy (HTTP 429, explicit do-not-retry response); not opened this session.
  9. Iodine-131/isotretinoin/thyrotropin alfa: Ophthalmopathy (first report with isotretinoin and thyrotropin alfa) in an elderly patient: case report. — Reactions Weekly 2006 (DOI 10.2165/00128415-200610940-00043). Drug-specific case report. Located via Crossref API metadata only; not opened this session. Listed for disclosure; not relevant to any of this dossier's graded categories (ophthalmopathy is a clinical outcome, not a nutrient finding) and not used as evidence.Located via Crossref metadata only; not independently opened this session.
  10. Drug-Induced Nutrient Depletions: What Pharmacists Need to Know. — US Pharmacist (consumer/professional circulating-claims source). Opened and searched for thyrotropin alfa, Thyrogen, recombinant TSH, and thyroid-stimulating hormone; no matches found. Used as negative evidence in the circulating-claim audit.
  11. Drug-Nutrient Depletion and Interaction Charts. — Chiro.org compilation (consumer/practitioner circulating-claims source). Opened and searched for thyrotropin alfa, Thyrogen, recombinant TSH, and thyroid-stimulating hormone; no matches found. Used as negative evidence in the circulating-claim audit.
  12. Thyrogen side effects. — Drugs.com consumer/professional drug-information page. Opened in full; confirms labeled adverse-reaction rates (nausea, fatigue, vomiting, "unusual tiredness or weakness") and used as negative evidence in the circulating-claim audit; no mineral, vitamin, or "detox" content found.
  13. Thyrogen (thyrotropin alfa for injection), patient information. — ThyCa: Thyroid Cancer Survivors' Association. Opened; page content was a 2014 FDA widened-dose-range approval announcement with no nutrient, energy, or gut-health claims. Used as negative evidence in the circulating-claim audit.
  14. PubMed search-listing pages (pubmed.ncbi.nlm.nih.gov) and NCBI eutils esearch. — Attempted for thyrotropin alfa plus oxidative stress, mitochondria, iron, copper, and microbiome terms. Rejected by the WebFetch proxy with HTTP 429 and an explicit do-not-retry instruction (search-listing pages), and by robots.txt disallowance (eutils.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov, ncbi.nlm.nih.gov/books). Not used as an evidence source this session; disclosed as a genuine tooling-access limitation.Blocked (HTTP 429 proxy rejection with do-not-retry instruction, and robots.txt disallowance) on every attempt this session.
  15. Europe PMC REST API, website, and europepmc.org frontend. — Attempted for thyrotropin alfa plus mitochondria/oxidative stress/microbiome/iron/copper terms. All three access points returned HTTP 429 (proxy rejection) or robots.txt disallowance. Not used as an evidence source this session; disclosed as a genuine tooling-access limitation.Blocked (HTTP 429 and robots.txt disallowance) on every attempt this session.
  16. Semantic Scholar API and web frontend; OpenAlex API. — Attempted for thyrotropin alfa/TSH plus mitochondria, ATP, oxidative stress, iron, and copper terms. Semantic Scholar returned HTTP 429 (API) and robots.txt disallowance (web frontend); OpenAlex returned persistent HTTP 429 from the target server on two separate attempts with backoff. Not used as an evidence source this session; disclosed as a genuine tooling-access limitation.Persistent HTTP 429 / robots.txt disallowance on every attempt this session.
  17. Google, Bing, and DuckDuckGo HTML web search; BASE search; Lens.org. — Attempted as alternatives to the blocked literature APIs and the exhausted WebSearch tool. Google and Bing returned robots.txt disallowance; DuckDuckGo's HTML endpoint returned a robots.txt fetch failure; BASE returned an access-denied bot-protection page (Anubis system); Lens.org returned HTTP 403. None usable this session.All blocked by robots.txt disallowance, bot-protection, or HTTP 403; not usable this session.
  18. WebSearch tool. — The first query attempted in this task ("Thyrogen thyrotropin alfa prescribing information DailyMed FDA label") returned "this session has used its web search budget (200 of 200 WebSearch calls)" before any results were produced. Not used as an evidence source this session; disclosed as a genuine tooling-access limitation, most likely reflecting concurrent use of the same account-level budget by other dossiers in this batch.Session-level WebSearch budget exhausted (200/200) before this task's first query completed.
  19. Taurog A, Lothrop ML, Estabrook RW. Improvements in the isolation procedure for thyroid peroxidase: nature of the heme prosthetic group. — Arch Biochem Biophys 1970;139(1):212-220 (DOI 10.1016/0003-9861(70)90064-0). Classic biochemical characterization study, drug-independent, Tier B established pharmacology/enzymology reference. Located and read via Crossref metadata and abstract-level detail during the Iron re-attempt. Confirms thyroid peroxidase's heme (iron) prosthetic group as established enzymology; does not discuss TSH, thyrotropin, or thyrotropin alfa regulation of this cofactor, and is cited in the Iron entry as the mechanistic premise, not as evidence of a drug effect.
  20. Alexander NM, Corcoran BJ. The reversible dissociation of thyroid iodide peroxidase into apoenzyme and prosthetic group. — J Biol Chem 1962;237(11):3407-3411 (DOI 10.1016/S0021-9258(18)81393-X). Classic biochemical characterization study, drug-independent, Tier B established pharmacology/enzymology reference. Located and read via Crossref metadata and abstract-level detail during the Iron re-attempt. Same use and same limitation as the Taurog et al. 1970 entry above: confirms the heme/iron cofactor structurally, states nothing about TSH or thyrotropin alfa regulation of it.
  21. DrugBank (go.drugbank.com). — Attempted for a thyrotropin alfa monograph page. Returned HTTP 403. Not used as an evidence source this session; disclosed as a tooling-access limitation. The ATC code and pharmacokinetic facts cited in this dossier come instead from the WHO ATC/DDD Index and the DailyMed label, both independently confirmed.HTTP 403 on the attempted page; not opened this session.